AKBA – akebia therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
Akebia Therapeutics (AKBA) had its price target lowered by BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights [Yahoo! Finance]
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
Form 8-K Akebia Therapeutics, For: Feb 26
Form SCHEDULE 13G Akebia Therapeutics, Filed by: STATE STREET CORP
Form 4 Akebia Therapeutics, For: Feb 02 Filed by: Malabre Richard C
Form 4 Akebia Therapeutics, For: Feb 02 Filed by: Grund Nicholas
Form 4 Akebia Therapeutics, For: Feb 02 Filed by: Burke Steven Keith
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.